Carnegie Mellon University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Pittsburgh PA United States (1900)

Organization Overview

First Clinical Trial
2017
NCT02606045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Barry Dewitt | Carnegie Mellon University

Active Ingredients

Drugs in Phase 3 Trials (2)

tranexamic acid (cyklokapron) (1 trial)

von Willebrand factor (recombinant) (Vonvendi) (1 trial)

Drugs in Phase 2 Trials (2)

epoetin (Epogen) (1 trial)

hydroxyurea (hydrea) (1 trial)

Drugs in Phase 1 Trials (1)

ethanol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 1)

Alcoholic Intoxication (Phase 1)

Alcoholism (Phase 1)

Binge Drinking (Phase 1)

Menorrhagia (Phase 3)

von Willebrand Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5